Clinical Trial Update: MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial (C-PRECISE-01) evaluated MEN1611 with cetuximab in metastatic colorectal cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• MEN1611 (MEN1611)

Snippet

Sponsor: Menarini Group | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-01